Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy versus letrozole in postmenopausal ER-positive primary breast cancer
2006-003596-12Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Dec 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole, fluorouracil, epirubicin, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by Imperial College London. Primary endpoints: Feasibility of patient recruitment, Feasibility of tissue collection and 1 more. Started Dec 2007; status: completed.
02
Drugs
letrozolefluorouracilepirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-003596-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003596-12.